Logo
x

Search

Subscribe Now

ind

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

  • November 19, 2021
Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large B-Cell Lymphoma

Antengene's Receives NMPA's IND Approval for P-Ib MATCH Study of ATG-008 (onatasertib) ATG-010 (selinexor) to Treat Diffuse Large...

  • November 2, 2021
Impact Receives US FDA's IND Clearance for IMP9064 to Treat Solid Tumor

Impact Receives US FDA's IND Clearance for IMP9064 to Treat Solid Tumor

  • October 29, 2021
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

  • October 15, 2021
Immunic's IMU-838 Receives the US FDA's IND Approval to Initiate P-III ENSURE & P-II CALLIPER Studies for RRMS & PMS

Immunic's IMU-838 Receives the US FDA's IND Approval to Initiate P-III ENSURE & P-II CALLIPER Studies for RRMS & PMS

  • July 6, 2021
Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

  • June 16, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.